Clinical Trial Update: A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating switching from etanercept to infliximab in moderate-to-severe psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Etanercept (etanercept)
• Infliximab (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2011-02-24